Alessandra Gianoncelli et al.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 29(4), 285-300 (2015-09-04)
Authorization to market a biosimilar product by the appropriate institutions is expected based on biosimilarity with its originator product. The analogy between the originator and its biosimilar(s) is assessed through safety, purity, and potency analyses. In this study, we proposed